PBO

RxBenefits Appoints Mark Campbell as Chief Pharmacy Officer

Retrieved on: 
Tuesday, January 30, 2024
Growth, Knowledge, Medicine, ALA, University, Patient, Safety, PBO, Doctor of Pharmacy, Investment, Health, Nursing

BIRMINGHAM, ALA., Jan. 30, 2024 (GLOBE NEWSWIRE) -- RxBenefits , the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO) , today announced Mark Campbell , PharmD, has been appointed to the company’s new Chief Pharmacy Officer position.

Key Points: 
  • BIRMINGHAM, ALA., Jan. 30, 2024 (GLOBE NEWSWIRE) -- RxBenefits , the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO) , today announced Mark Campbell , PharmD, has been appointed to the company’s new Chief Pharmacy Officer position.
  • Campbell, whose experience covers an impressive 27-year career in the pharmacy industry, has led RxBenefits’ Clinical Services team since 2017.
  • As Chief Pharmacy Officer, Campbell will increase the company’s focus on using pharmaceutical insights to help facilitate better health outcomes.
  • With his promotion, Campbell became the fifth member of RxBenefits’ C-suite, joining Barnes – to whom he now reports – as well as President and Chief Operating Officer Robert Gamble, Chief Financial Officer Thad Kwiatkowski, and Chief Client Officer Nathan White.

RxBenefits Partners with Springbuk in Innovative New Health Intelligence Marketplace for Employers and Benefits Advisors

Retrieved on: 
Tuesday, January 16, 2024
Partnership, Pharmacy, PBO, Safety, ALA, Health, Risk management

BIRMINGHAM, ALA., Jan. 16, 2024 (GLOBE NEWSWIRE) -- RxBenefits , the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO) , today announced a strategic partnership with Springbuk , the leading health intelligence platform for employers and benefits advisors.

Key Points: 
  • BIRMINGHAM, ALA., Jan. 16, 2024 (GLOBE NEWSWIRE) -- RxBenefits , the employee benefits industry’s first technology-enabled pharmacy benefits optimizer (PBO) , today announced a strategic partnership with Springbuk , the leading health intelligence platform for employers and benefits advisors.
  • The Springbuk Activate marketplace matches employers with potential partners using underlying plan data, including their population's health needs or risks, showing them potential opportunities in savings and program engagement – all in one place.
  • Integrating RxBenefits’ pharmacy benefit optimization with information in the Springbuk Activate partner marketplace will create a conduit to enhance healthcare outcomes through data-driven insights and personalized care.
  • “Employers need sustainable ways to manage healthcare costs, without negatively impacting member health and safety,” said Wendy Barnes, CEO of RxBenefits .

AMD Reveals Next-Gen Desktop Processors for Extreme PC Gaming and Creator Performance

Retrieved on: 
Monday, January 8, 2024
Ecosystem, OEM, Radeon, DIY, AM5, AMD, PBO, AI, 3D, AM4, CPU, NPU, Computing, Longevity, CES, Video game

LAS VEGAS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Today, ahead of CES 2024, AMD (NASDAQ: AMD) announced new products expanding its desktop portfolio, delivering premium experiences to gamers, content creators and everyday users through extraordinary performance and the power of personal AI processing. AMD is introducing the new AMD Ryzen™ 8000G Series desktop processors for the AM5 platform, including the Ryzen™ 7 8700G, with the world’s most powerful built-in graphics.1 AMD is also bringing the power of a dedicated AI neural processing unit (NPU) to desktop PC processors for the first time with the introduction of Ryzen™ AI to unlock more AI capabilities for consumers and improve productivity, efficiency, and advanced collaboration.

Key Points: 
  • Building on the unprecedented longevity of socket AM4, AMD is introducing new Ryzen™ 5000 processors, offering users even more choices when it comes to building a system for productivity, gaming, or content creation.
  • The new offerings include the new Ryzen 7 5700X3D, leveraging powerful 3D V-Cache™ technology to provide gamers with a massive boost in gaming performance.
  • This year, we are expanding our AI leadership to desktop computing through our Ryzen 8000G Series processors.
  • We’re excited to lead the AI PC era together with our close OEM and ecosystem partners.”
    AMD Ryzen™ 8000G Series is the ultimate all-in-one desktop processor.

WiMi Developed PBO-Based Dynamic Optimization Algorithm That Can Be Applied to Blockchain and Bitcoin Trading Strategies

Retrieved on: 
Monday, January 8, 2024
Cloud, Blockchain, Risk, Probability, Overfitting, Mining, WIMI, CSCV, PBO, Augmented reality, Holography, Algorithm, Cryptocurrency

In order to obtain models that perform better out-of-sample, WiMi has developed a dynamic optimization algorithm based on PBO, namely the "PBO-DOA algorithm".

Key Points: 
  • In order to obtain models that perform better out-of-sample, WiMi has developed a dynamic optimization algorithm based on PBO, namely the "PBO-DOA algorithm".
  • This algorithm is important in quantitative trading because it can dynamically optimize the model's parameters to help investors build optimal portfolios.
  • WiMi's PBO-DOA allows for more scientific optimization of blockchain and bitcoin trading strategies, thereby increasing portfolio returns and controlling risk.
  • Algorithms in blockchain and bitcoin trading strategies are over-optimizing the weight allocation of portfolios, maximizing returns, and controlling risks.

BRIGHTLINE AND ISLANDS OF THE BAHAMAS DEBUT PARTNERSHIP

Retrieved on: 
Monday, December 11, 2023
Holiday, Very important person, MIA, Senior, Miami International Airport, History, Orlando Health, Investment, PBO, Fort Lauderdale–Hollywood International Airport, Island, Fortification, Airport, FTL, Partnership, Junkanoo, MCO, Orlando International Airport, Travel, Airline, Tourism, The Bahamas, Brightline, Central Florida

MIAMI, Dec. 11, 2023 /PRNewswire/ -- Brightline, the nation's only provider of modern, eco-friendly intercity passenger rail, and The Islands of The Bahamas unveiled the first wrapped train showcasing a new partnership that celebrates the connection between Florida's most visited regions (South and Central Florida) and the nearby Bahama Islands. Brightline and The Islands of The Bahamas commemorated the new partnership with celebratory events at Brightline Orlando Station in partnership with Orlando Health on December 6 and Brightline MiamiCentral on December 7.

Key Points: 
  • Brightline and The Islands of The Bahamas commemorated the new partnership with celebratory events at Brightline Orlando Station in partnership with Orlando Health on December 6 and Brightline MiamiCentral on December 7.
  • To enhance accessibility and deepen the bond between these locales, nonstop flights from Orlando and South Florida to The Bahamas are available from all international airports (MCO, PBO, FTL and MIA) closely accessible with Brightline.
  • "Brightline represents this connection in a very special way and we are thrilled to roll out this partnership."
  • "The Islands of The Bahamas-branded Brightline train represents our partnership of connectivity, promoting travel, tourism and what makes the 16 islands so special and close," said Johanna Rojas, Senior Vice President of Sales and Partnerships for Brightline.

RxBenefits Among Inc.'s Second Annual Power Partners Award Winners

Retrieved on: 
Tuesday, October 24, 2023
Health, Life, Elijah Cummings Lower Drug Costs Now Act, Organization, B2B, Entrepreneurship, Advertising, Marketing, Pharmacy, Record, PBO, Safety, Patient

BIRMINGHAM, Ala., Oct. 24, 2023 /PRNewswire-PRWeb/ -- RxBenefits, the employee benefits industry's first technology-enabled pharmacy benefits optimizer (PBO), has been honored by Inc. Business Media as a winner in the second annual Power Partner Awards. The program recognizes B2B organizations across the globe that have proven track records supporting entrepreneurs and helping startups grow. The list recognizes 389 firms in health and wellness, marketing and advertising, financial services, legal, logistics, and productivity, as well as other areas of business.

Key Points: 
  • BIRMINGHAM, Ala., Oct. 24, 2023 /PRNewswire-PRWeb/ -- RxBenefits , the employee benefits industry's first technology-enabled pharmacy benefits optimizer (PBO) , has been honored by Inc. Business Media as a winner in the second annual Power Partner Awards .
  • The program recognizes B2B organizations across the globe that have proven track records supporting entrepreneurs and helping startups grow.
  • Congratulations to all the winners in the 2023 Power Partner Awards!"
  • To view the complete list Power Partner Award winners, go to: https://www.inc.com/power-partner-awards/2023
    The November 2023 Issue of Inc. magazine is available online now at https://www.inc.com/magazine and will be on newsstands beginning October 31, 2023.

Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease

Retrieved on: 
Tuesday, October 10, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, MSD, NYSE, Abstract, Breast cancer, Brentuximab vedotin, INT, Trastuzumab, RCC, Survival, Endometrial cancer, PEM, NRG, ESMO, Merck & Co., Webcast, Belzutifan, European Society for Medical Oncology, ADC, Research, TUC, KRAS, Lung cancer, RAS, AstraZeneca, EC, Adenocarcinoma, Head, TNBC, MRK, Pembrolizumab, Everolimus, CRC, Cancer, Olaparib, EFS, Quality of life (healthcare), SWOG, Congress, LBA32, LBA21, PBO, Chemoradiotherapy, CP, Safety, MBC, Patient, Pharmaceutical industry, Birth control, Medical imaging, Animal feed, Vaccine, Tras, Merck, NSCLC, Eisai

The event will take place virtually and will be accessible via webcast.

Key Points: 
  • The event will take place virtually and will be accessible via webcast.
  • Safety and preliminary efficacy of the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC.
  • Pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIB-IV melanoma from SWOG S1801.
  • mRNA-4157 (V940) individualized neoantigen therapy + pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of response.

RxBenefits Announces 340B Solution Designed to Support In-House Pharmacy Needs of Hospitals and Other Covered Entities

Retrieved on: 
Tuesday, September 26, 2023
Health care, Hospital, COVID-19, Knowledge, House, Prescription, PBO, Patient, Pharmacy, Consultant, Health insurance

BIRMINGHAM, Ala., Sept. 26, 2023 /PRNewswire-PRWeb/ -- RxBenefits, the employee benefits industry's first technology-enabled pharmacy benefits optimizer (PBO), today announced the launch of Optimize 340B, a solution designed to maximize the value of 340B on the prescription plans of hospitals and 340B grantees. Optimize 340B combines comprehensive analytics and expert insights to unlock the financial potential of employee-eligible 340B claims and referrals for hospitals and other covered entities.

Key Points: 
  • Optimize 340B combines comprehensive analytics and expert insights to unlock the financial potential of employee-eligible 340B claims and referrals for hospitals and other covered entities.
  • Optimize 340B is a unique management solution that encourages in- house pharmacy utilization by capturing and identifying employee-eligible claims, maximizing in- house plan savings and productivity.
  • Working with an experienced partner like RxBenefits can help covered entities capitalize on these savings and optimize their 340B program while remaining compliant with all regulations.
  • To learn more about Optimize 340B and RxBenefits' portfolio of products designed to suit hospitals' unique pharmacy needs, please visit https://www.rxbenefits.com/solutions/ .

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly

Retrieved on: 
Sunday, September 10, 2023
Injection, Endocrinology, Obesity, Carcinoid syndrome, Diabetes, Diarrhea, FISU World University Games, Hyperparathyroidism, Hyperinsulinism, Congenital adrenal hyperplasia, PAL, Medicine, Arthralgia, Abdominal pain, ID, Acromegaly, Patient, Webcast, Nausea, Medical school, G protein, PBO, Headache, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry

The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine (PAL) treatment arm vs placebo (PBO) arm (80% vs. 100% respectively).

Key Points: 
  • The frequency of participants with at least one treatment emergent adverse event (TEAE) was comparable in the paltusotine (PAL) treatment arm vs placebo (PBO) arm (80% vs. 100% respectively).
  • The frequency of adverse events considered related to acromegaly was notably lower in paltusotine treated participants compared to placebo treated participants (30% vs. 86% respectively).
  • “We designed paltusotine to be the preferred therapeutic option for people living with acromegaly.
  • The Company is also conducting an open-label Phase 2 study to evaluate paltusotine in patients with carcinoid syndrome and intends to report preliminary results later this year.

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023

Retrieved on: 
Saturday, June 17, 2023
ENDO, Mayo Clinic, Pathway, Hypoparathyroidism, Saint Andrew's Society, Patient, Southern Transcon, Endocrine Society, Vitamin D, Clinical professor, PBO, Safety, OLE, Disease, Pharmaceutical industry, Medicine

COPENHAGEN, Denmark, June 17, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today reported one-year (Week 52) data from its ongoing Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism. The data showed that treatment with TransCon PTH resulted in sustained improvements through Week 52, as well as safety and tolerability similar to that reported for the initial 26-week blinded portion of the trial. The data were presented by Bart Clarke, M.D., endocrinologist and Professor of Medicine at the Mayo Clinic (Rochester, MN), during ENDO 2023, the annual meeting of the Endocrine Society being held in Chicago.

Key Points: 
  • The data were presented by Bart Clarke, M.D., endocrinologist and Professor of Medicine at the Mayo Clinic (Rochester, MN), during ENDO 2023, the annual meeting of the Endocrine Society being held in Chicago.
  • Bone mineral density (BMD) Z-scores continued to trend toward age- and sex-matched norms with 52 weeks of TransCon PTH treatment.
  • TransCon PTH normalized 24-hour urine calcium through Week 52, regardless of initial randomization (placebo or TransCon PTH).
  • TransCon PTH continued to be well-tolerated in the Phase 3 open-label extension, with no new safety signal identified.